Research advances in coronavirus disease 2019-related liver injury
10.3969/j.issn.1001-5256.2022.04.039
- VernacularTitle:新型冠状病毒肺炎相关肝损伤研究进展
- Author:
Hao CUI
1
;
Jing LIANG
1
;
Huiling XIANG
2
Author Information
1. The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China;Department of Hepatology, Tianjin Third Central Hospital, Tianjin 300170, China
2. Department of Hepatology, Tianjin Third Central Hospital, Tianjin 300170, China
- Publication Type:Reviews
- Keywords:
Coronavirus Disease 2019;
Hepatic Insufficiency;
Drug Induced Liver Injury;
Therapeutics
- From:
Journal of Clinical Hepatology
2022;38(4):931-935
- CountryChina
- Language:Chinese
-
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic has brought great threats and challenges to global public health and has changed the priorities of medical resource allocation. A considerable proportion of patients with liver injury is observed during the clinical diagnosis and treatment of COVID-19, especially in those with a severe or critical illness. This article summarizes the epidemiology, mechanism, clinical features, and treatment of liver injury caused by COVID-19, in order to help clinicians with decision making and treatment optimization.
